BioSpace News Archive

a highly interactive forum uniting senior executives and scientists from the pharmaceutical and biotech industries to explore advancements in immunotherapy. The event will dive into critical focus areas including immunogenicity, immune regulation, translational immunology, immune biomarkers, and clinical development

This exclusive, high-level forum is designed for senior scientists and executives to tackle the toughest challenges in therapeutic innovation, clinical strategy, and CMC development for oligonucleotides and peptides. With expert-led roundtables, spotlight and poster presentations, and 1:1 networking opportunities, the agenda features insights from XAIGene, Ultragenyx, Grann Pharmaceuticals, and more. Topics span circular DNA, mRNA–LNP therapies, peptide-enhanced AAV delivery, and scalable manufacturing solutions.

Jonathan Kagan, PhD, is the Distinguished Scientist at Corner Therapeutics, an immunotherapy company pioneering novel approaches to cancer and infection, a Professor of Pediatrics at Harvard Medical School and a Staff Scientist at Boston Children’s Hospital.

In December 2024, Dewpoint Therapeutics CEO Ameet Nathwani said the biotech’s cash runway would last until the third quarter of 2025.

Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or expand manufacturing sites in the U.S.

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised concerns that Health Secretary RFK Jr. could abolish or overhaul the group.